🌍·1d agodiscovery
TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
Publisher
C
CancerNetwork
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- CancerNetwork
- Region
- Global
- Scope
- discovery
- Published
- July 5, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: CancerNetwork
Scope: discovery
Related coverage
More related coverage
UK Health Security Agency/3h ago
Inadvertent vaccination in pregnancy (VIP)
Advice for health professionals on pregnant women who are inadvertently vaccinated against chicken p...
Tech Times/3h ago
HSBC Drops Pfizer to Hold: Seagen ADC Miss Leaves $43B Bet Without Catalyst
조선일보/4h ago
Biosimilar Race Heats Up for $48 Trillion Keytruda Market
qz.com/4h ago